Clinical Trial Update: A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for a Phase 1/2 study of AK129 with or without AK117 in PD-L1–refractory classical Hodgkin lymphoma, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma Classical

Drugs mentioned

• AK117 (AK117)
• AK129 (anti-PD-1 and LAG-3 bispecific antibody)

Snippet

Sponsor: Akeso | Conditions: Classic Hodgkin Lymphoma | Phase 1, Phase 2 | Status: RECRUITING